Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828860) titled 'Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Corvus Pharmaceuticals, Inc.
Condition:
Hidradenitis Suppurativa (HS)
Intervention:
Drug: Soquelitinib
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 25
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07828860
Disclaimer: Curated...